{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,2]],"date-time":"2025-06-02T13:27:56Z","timestamp":1748870876618,"version":"3.37.3"},"reference-count":18,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2021,9,2]],"date-time":"2021-09-02T00:00:00Z","timestamp":1630540800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Strahlenther Onkol"],"published-print":{"date-parts":[[2022,1]]},"DOI":"10.1007\/s00066-021-01838-6","type":"journal-article","created":{"date-parts":[[2021,9,3]],"date-time":"2021-09-03T20:59:34Z","timestamp":1630702774000},"page":"73-79","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Impact of postoperative radiotherapy on the outcomes of resected adrenocortical carcinoma\u2014a\u00a0real-world, population-based study"],"prefix":"10.1007","volume":"198","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5117-2502","authenticated-orcid":false,"given":"Omar","family":"Abdel-Rahman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2021,9,2]]},"reference":[{"issue":"2","key":"1838_CR1","doi-asserted-by":"publisher","first-page":"R51","DOI":"10.1530\/EJE-20-0800","volume":"184","author":"J Crona","year":"2021","unstructured":"Crona\u00a0J, Baudin\u00a0E, Terzolo\u00a0M, Chrisoulidou\u00a0A, Angelousi\u00a0A, Ronchi\u00a0CL et al (2021) ENSAT registry-based randomized clinical trials for adrenocortical carcinoma. Eur J Endocrinol 184(2):R51\u2013R59","journal-title":"Eur J Endocrinol"},{"key":"1838_CR2","doi-asserted-by":"publisher","DOI":"10.1007\/s40618-021-01618-0","author":"O Abdel-Rahman","year":"2021","unstructured":"Abdel-Rahman\u00a0O (2021) Revisiting the AJCC staging system of adrenocortical carcinoma. J\u00a0Endocrinol Invest. https:\/\/doi.org\/10.1007\/s40618-021-01618-0","journal-title":"J Endocrinol Invest"},{"issue":"5","key":"1838_CR3","doi-asserted-by":"publisher","first-page":"2246","DOI":"10.21037\/tau.2020.01.11","volume":"10","author":"DM Buller","year":"2021","unstructured":"Buller\u00a0DM, Hennessey\u00a0AM, Ristau\u00a0BT (2021) Open versus minimally invasive surgery for suspected adrenocortical carcinoma. Transl Androl Urol 10(5):2246\u20132263","journal-title":"Transl Androl Urol"},{"issue":"2","key":"1838_CR4","doi-asserted-by":"publisher","first-page":"508","DOI":"10.3390\/cancers12020508","volume":"12","author":"S Bedrose","year":"2020","unstructured":"Bedrose\u00a0S, Daher\u00a0M, Altameemi\u00a0L, Habra\u00a0MA (2020) Adjuvant therapy in adrenocortical carcinoma: reflections and future directions. Cancers (Basel) 12(2):508","journal-title":"Cancers (Basel)"},{"issue":"1","key":"1838_CR5","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1007\/s12020-019-01918-9","volume":"65","author":"I Kostiainen","year":"2019","unstructured":"Kostiainen\u00a0I, Hakaste\u00a0L, Kejo\u00a0P, Parviainen\u00a0H, Laine\u00a0T, L\u00f6yttyniemi\u00a0E et\u00a0al (2019) Adrenocortical carcinoma: presentation and outcome of a\u00a0contemporary patient series. Endocrine 65(1):166\u2013174","journal-title":"Endocrine"},{"issue":"4","key":"1838_CR6","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3390\/jpm11040269","volume":"11","author":"V Basile","year":"2021","unstructured":"Basile\u00a0V, Puglisi\u00a0S, Altieri\u00a0B, Canu\u00a0L, Lib\u00e8\u00a0R, Ceccato\u00a0F et\u00a0al (2021) What is the optimal duration of adjuvant mitotane therapy in adrenocortical carcinoma? An unanswered question. J\u00a0Pers Med 11(4):269","journal-title":"J Pers Med"},{"issue":"6","key":"1838_CR7","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.clbc.2018.07.016","volume":"18","author":"O Abdel-Rahman","year":"2018","unstructured":"Abdel-Rahman\u00a0O (2018) Impact of regional nodal irradiation on the outcomes of N1 breast cancer patients referred for adjuvant treatment: a patient-level pooled analysis of 2 clinical trials. Clin Breast Cancer 18(6):504\u2013510","journal-title":"Clin Breast Cancer"},{"issue":"4","key":"1838_CR8","doi-asserted-by":"publisher","first-page":"611","DOI":"10.1016\/j.adro.2018.07.007","volume":"3","author":"O Abdel-Rahman","year":"2018","unstructured":"Abdel-Rahman\u00a0O, Elhalawani\u00a0HM, Allen\u00a0PK, Holliday\u00a0EB (2018) Utilization of short-course radiation therapy for patients with nonmetastatic rectal adenocarcinoma in the United States. Adv Radiat Oncol 3(4):611\u2013620","journal-title":"Adv Radiat Oncol"},{"issue":"6","key":"1838_CR9","doi-asserted-by":"publisher","first-page":"693","DOI":"10.6004\/jnccn.2018.0056","volume":"16","author":"MH Shah","year":"2018","unstructured":"Shah\u00a0MH, Goldner\u00a0WS, Halfdanarson\u00a0TR, Bergsland\u00a0E, Berlin\u00a0JD, Halperin\u00a0D et\u00a0al (2018) NCCN guidelines insights: neuroendocrine and adrenal tumors, version 2.2018. J\u00a0Natl Compr Canc Netw 16(6):693\u2013702","journal-title":"J Natl Compr Canc Netw"},{"issue":"11","key":"1838_CR10","doi-asserted-by":"publisher","first-page":"1476","DOI":"10.1016\/j.annonc.2020.08.2099","volume":"31","author":"M Fassnacht","year":"2020","unstructured":"Fassnacht\u00a0M, Assie\u00a0G, Baudin\u00a0E, Eisenhofer\u00a0G, de la Fouchardiere\u00a0C, Haak\u00a0HR et al (2020) Adrenocortical carcinomas and malignant phaeochromocytomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 31(11):1476\u20131490","journal-title":"Ann Oncol"},{"issue":"4","key":"1838_CR11","doi-asserted-by":"publisher","first-page":"G1","DOI":"10.1530\/EJE-18-0608","volume":"179","author":"M Fassnacht","year":"2018","unstructured":"Fassnacht\u00a0M, Dekkers\u00a0OM, Else\u00a0T, Baudin\u00a0E, Berruti\u00a0A, de Krijger\u00a0R et\u00a0al (2018) European Society of Endocrinology clinical practice guidelines on the management of adrenocortical carcinoma in adults, in collaboration with the European Network for the Study of Adrenal Tumors. Eur J Endocrinol 179(4):G1\u2013G46","journal-title":"Eur J Endocrinol"},{"key":"1838_CR12","unstructured":"Surveillance, Epidemiology, and End Results (SEER) Program (2020) SEER*Stat database: incidence\u2014SEER research plus data, 18 registries, Nov 2019 sub (2000\u20132017)\u2014linked to county attributes\u2014total U.S., 1969\u20132018 counties, National Cancer Institute, DCCPS, surveillance research program. www.seer.cancer.gov (based on the November 2019 submission). Accessed: 31. March 2021"},{"issue":"23","key":"1838_CR13","doi-asserted-by":"publisher","first-page":"2372","DOI":"10.1056\/NEJMoa063360","volume":"356","author":"M Terzolo","year":"2007","unstructured":"Terzolo\u00a0M, Angeli\u00a0A, Fassnacht\u00a0M, Daffara\u00a0F, Tauchmanova\u00a0L, Conton\u00a0PA et\u00a0al (2007) Adjuvant mitotane treatment for adrenocortical carcinoma. N\u00a0Engl J Med 356(23):2372\u20132380","journal-title":"N Engl J Med"},{"key":"1838_CR14","doi-asserted-by":"publisher","DOI":"10.1155\/2018\/9362108","author":"Y Tang","year":"2018","unstructured":"Tang\u00a0Y, Liu\u00a0Z, Zou\u00a0Z, Liang\u00a0J, Lu\u00a0Y, Zhu\u00a0Y (2018) Benefits of adjuvant mitotane after resection of adrenocortical carcinoma: a systematic review and meta-analysis. Biomed Res Int. https:\/\/doi.org\/10.1155\/2018\/9362108","journal-title":"Biomed Res Int"},{"issue":"1","key":"1838_CR15","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1007\/s10549-017-4577-x","volume":"168","author":"O Abdel-Rahman","year":"2018","unstructured":"Abdel-Rahman\u00a0O (2018) Validation of the 8th AJCC prognostic staging system for breast cancer in a\u00a0population-based setting. Breast Cancer Res Treat 168(1):269\u2013275","journal-title":"Breast Cancer Res Treat"},{"issue":"6","key":"1838_CR16","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1089\/thy.2018.0775","volume":"30","author":"A Zahedi","year":"2020","unstructured":"Zahedi\u00a0A, Bondaz\u00a0L, Rajaraman\u00a0M, Leslie\u00a0WD, Jefford\u00a0C, Young\u00a0JEM et\u00a0al (2020) Risk for thyroid cancer recurrence is higher in men than in women independent of disease stage at presentation. Thyroid 30(6):871\u2013877","journal-title":"Thyroid"},{"issue":"2","key":"1838_CR17","doi-asserted-by":"publisher","first-page":"252","DOI":"10.1016\/j.ijrobp.2015.01.007","volume":"92","author":"A Sabolch","year":"2015","unstructured":"Sabolch\u00a0A, Else\u00a0T, Griffith\u00a0KA, Ben-Josef\u00a0E, Williams\u00a0A, Miller\u00a0BS et al (2015) Adjuvant radiation therapy improves local control after surgical resection in patients with\u00a0localized adrenocortical carcinoma. Int J Radiat Oncol Biol Phys 92(2):252\u2013259","journal-title":"Int J Radiat Oncol Biol Phys"},{"issue":"1","key":"1838_CR18","doi-asserted-by":"publisher","first-page":"118","DOI":"10.1186\/s13014-020-01533-3","volume":"15","author":"J Zhu","year":"2020","unstructured":"Zhu\u00a0J, Zheng\u00a0Z, Shen\u00a0J, Lian\u00a0X, Miao\u00a0Z, Shen\u00a0J et al (2020) Efficacy of adjuvant radiotherapy for treatment of adrenocortical carcinoma: a\u00a0retrospective study and an updated meta-analysis. Radiat Oncol 15(1):118","journal-title":"Radiat Oncol"}],"container-title":["Strahlentherapie und Onkologie"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01838-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00066-021-01838-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00066-021-01838-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,14]],"date-time":"2022-01-14T12:02:55Z","timestamp":1642161775000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00066-021-01838-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9,2]]},"references-count":18,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2022,1]]}},"alternative-id":["1838"],"URL":"https:\/\/doi.org\/10.1007\/s00066-021-01838-6","relation":{},"ISSN":["0179-7158","1439-099X"],"issn-type":[{"type":"print","value":"0179-7158"},{"type":"electronic","value":"1439-099X"}],"subject":[],"published":{"date-parts":[[2021,9,2]]},"assertion":[{"value":"4 April 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 August 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 September 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"O.\u00a0Abdel-Rahman: Advisory board Eisai Canada, Lilly Canada, and Roche Canada.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"As this study is based on a publicly available database without identifying patient information, informed consent was not needed.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical standards"}}]}}